Capecitabine: A new oral fluoropyrimidine

Cancer Practice

Volumn 6, Issue 5, 1998, Pages 302-304

  Ignoffo, Robert J ^a  

^a UNIVERSITY OF SAN FRANCISCO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CLINICAL TRIAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG EFFECT; DRUG POTENCY; GASTROINTESTINAL TOXICITY; HUMAN; METASTASIS POTENTIAL; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; REVIEW; STOMATITIS; THROMBOCYTOPENIA;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; DEOXYCYTIDINE; HUMANS; NEOPLASMS;

EID: 0031715937     PISSN: 10654704     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-5394.1998.00028.x     Document Type: Review

References (13)

1. Ishitsuka H, Miwa M, Ishikawa T, et al. Capecitabine: an orally available fluoropyrimidine with tumor selective activity. Proc Am Assoc Cancer Res. 1995;36:407.
2. Heggie GD, Sommadossi JP, Cross DS, Huster WJ, Diasio RB. Clinical pharmacokinetics of fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res. 1987;47:2203-2206.
3. Ishikawa T, Utoh M, Sawada N, et al. Xeloda (capecitabine): an orally available tumor-selective fluoropyrimidine carbamate. Proc ASCO. 1997;16:208a(abstr 727).
4. Data on file at Hoffman-LaRoche, RO-09-1978, 1998.
5. Sawada N, Ishikawa T, Fukase Y, et al. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res. 1998;4:1013-1019.
6. Budman DR, Meropol NJ, Reigner B, et al. Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. J Clin Oncol. 1998;16:1795-1802.
7. Khoury P, Villalone-Calero M, Blum J, et al. Phase I study of capecitabine in combination with paclitaxel in patients with previously treated metastatic breast cancer. Proc ASCO. 1998; 17:290(abstr 793).
8. Pronk L, Vasey AP, Sparreboom RJ, et al. A matrix-designed phase I dose-finding and pharmacokinetic study of the combination of Xeloda plus Taxotere. Proc ASCO. 1998;17: 212a(abstr 816).
9. Reigner B, Verweij J, Luc D, et al. Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients. Clin Cancer Res. 1998; 4:941-948.
10. O'Shaunghnessy J, Moiseyenko V, Bell D, et al. A randomized phase II study of Xeloda (capecitabine) versus CMF as first line chemotherapy of breast cancer in women aged ≥ 55 years. Proc ASCO. 1998;17:103a(abstr 398).
11. Blum JL, LoRusso PM, Vogel C, et al. A multicenter trial of Xeloda (capecitabine) in paclitaxel-refractory metastatic breast cancer (MBC). Proc ASCO. 1998;17:209(abstr 476).
12. O'Reilly SM, Moiseyenko V, Talbot DC, et al. A randomized phase II study of Xeloda® (capecitabine) vs paclitaxel in breast cancer patients failing previous anthracycline therapy. Proc ASCO. 1998;17:(abstr 627).
13. Findlay M, Van Cutsem E, Kocha W, et al. A randomized phase II study of Xeloda™ (capecitabine) in patients with advanced colorectal cancer. Proc ASCO. 1998;17:227a(abstr 798).